Portal de investigação
Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement
Autores da FMUP
Participantes de fora da FMUP
- Trindade, FF
- Almeida-Coelho, J
- Arbones, ML
- Leite-Moreira, A
- Vitorino, R
Unidades de investigação
Abstract
Abstract no disponible
Filiações
Filiações não disponíveis
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Cardiac Remodelling and “Recovery” in Pregnancy as a Model to Understand the Mechanisms of CV Diseases.
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Observacional Académico (PERIMYR) . SP Cardiologia . 2019
Remodelling adversely impacts arrhythmic outcome following isolated aortic valve replacement surgery
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico (Remodelling) . 2020
Potencial Role of microRNAs as biomakers and therapeutic targets during left ventricular reverse remodelling
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico . 2022
The cross-talk between adipose tissue and heart
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico . 2022
The Heart under Pressure: Mechanisms underlying HEpEF Secondary to chronic pressure Overload or Metabolic Syndrome
Investigador Principal: Inês Maria Falcão Sousa Pires Marques
Estudo Clínico Académico . 2020
Citar a publicação
Trindade,FF,Almeida,J,Saraiva,F,Arbones,ML,Leite,A,Vitorino,R,Falcao,I. Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA:Wiley-Blackwell. 2023 p.p. 439-440.
